SGMOQ — SANGAMO THERAPEUTICS, INC

—
· Health Care · Biotechnology · CIK 1001233 ·
Last close
$0.11
Market Cap
$45.57M
52W High
$0.60
52W Low
$0.01
ADV30
1,330,713
Next earnings
2026-11-30

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Mar 2026 1,442,000 — -31,946,000 -30,995,000 59,965,000 27,586,000 78,920,000
Dec 2025 14,228,000 — -24,968,000 -37,419,000 59,745,000 20,948,000 74,013,000
Sep 2025 581,000 — -35,553,000 -34,930,000 88,643,000 29,616,000 82,400,000
Jun 2025 18,306,000 — -17,855,000 -19,986,000 97,558,000 38,344,000 77,956,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-90,341,000
Investing CF
$-115,000
Financing CF
$89,314,000
CapEx
$-243,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-21

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,658,244,000
Inventory
—
Receivables
$6,364,000
ST Investments
$0
EBIT TTM
$-110,322,000
Pretax Income TTM
$-124,017,000
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$34,557,000
EBITDA
$-106,662,000
Free Cash Flow
$-48,575,248
Enterprise Value
$49,746,440
Total Cash
$27,586,000
Total Debt
$19,332,000
Shares Out
414,288,847
Trailing EPS
$-0.38
Book Value
$-0.05
ROE
—
ROA
-94.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 39,552,000 -108,004,000 -122,932,000 59,745,000 74,013,000 -14,268,000 -97,208,000
Dec 2024 57,800,000 -98,448,000 -97,941,000 101,635,000 78,865,000 22,770,000 -67,139,000
Dec 2023 176,232,000 -118,992,000 -257,831,000 165,320,000 82,433,000 82,887,000 -224,842,000
Dec 2022 111,299,000 -201,281,000 -192,278,000 562,509,000 267,551,000 294,958,000 -223,627,000

TTM Snapshot

Revenues TTM
$34,557,000
NetIncome TTM
$-123,330,000
OpCashFlow TTM
—
Assets (Latest)
$59,965,000
Forward EPS
$-0.10

Peers — same industry

TickerNameMarket CapLastDaily %
INKT MiNK Therapeutics, Inc. $47.67M $9.28 —
IMA ImageneBio, Inc. $48.58M $3.90 —
ELOX Eloxx Pharmaceuticals, Inc. $40.34M $11.74 —
ELUT ELUTIA INC. $37.91M $0.85 —
TVGN Tevogen Inc. $37.05M $5.69 —

News headlines (Yahoo Finance, 1h cache)

Global Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and Intellia
2026-10-29 15:30 · Yahoo
Sangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain Program
2026-10-13 20:01 · Yahoo
Fabry Disease Market Outlook: 6 Upcoming Therapies Set to Influence the Future Market Landscape | DelveInsight
2026-10-01 14:31 · Yahoo
PTC takes a chance on Sangamo’s Fabry disease gene therapy
2026-08-13 11:10 · Yahoo
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
2026-09-21 20:30 · Yahoo
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
2026-08-12 20:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.